Probiotics in diverticular disease of the colon: An open label study

Journal of Gastrointestinal and Liver Diseases

Volumn 19, Issue 1, 2010, Pages 31-36

  Lamiki, Pepu ^a   Tsuchiya, Junji ^a   Pathak, Surajit ^b   Okura, Ruichi ^a   Solimene, Umberto ^c   Jain, Shalini ^d   Kawakita, Shichiro ^a   Marotta, Francesco ^e  

^a Tokyo Management College   (Japan)

^b UNIVERSITY OF KALYANI   (India)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^e S Giuseppe Hospital   (Italy)

Author keywords

Constipation predominant; Diverticular disease; Probiotics; Recurrence; Symbiotics

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; LAXATIVE; PROBIOTIC AGENT; SPASMOLYTIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL GENOME; BIFIDOBACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIA; COLON DIVERTICULOSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENTEROPATHY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; MALE; NONHUMAN; OPEN STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

ABDOMINAL PAIN; AGED; BIFIDOBACTERIUM; COLON; CONSTIPATION; DIVERTICULUM, COLON; DNA, BACTERIAL; FECES; FEMALE; HUMANS; LACTOBACILLUS ACIDOPHILUS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROBIOTICS; PROSPECTIVE STUDIES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951163668     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Sheth AA, Longo W, Floch MH. Diverticular disease and diverticulitis. Am J Gastroenterol 2008; 103: 1550-1556.
2. Comparato G, Fanigliulo L, Aragona G, et al. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? Dig Dis 2007; 25: 252-259.
3. Latella G, Pimpo MT, Sottili S, et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003; 18: 55-62.
4. Siitonen S, Vapaatalo H, Salminen S, et al. Effect of Lactobacillus GG yoghurt in the prevention of antibiotic-associated diarrhoea. Ann Med 1990; 22: 57-59.
5. Katelaris PH, Salam I, Farthing MJ. Lactobacilli to prevent traveller's diarrhoea? N Engl J Med 1995; 333: 1360-1361.
6. Xiao SD, Zhang DZ, Lu H, et al. Multicenter randomized controlled trial of heat-killed Lactobacillus acidophilus LB in patients with chronic diarrhoea. J Dig Dis 2002; 3: 167-171.
7. Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus, Lactobacillus casei in high fructose fed rats. Nutrition 2007; 23: 62-68.
8. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309.
9. Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr 2002; 88 (Suppl 1): S39-49.
10. Su P, Henriksson A, Mitchell H. Prebiotics enhance survival and prolong the retention period of specific probiotic inocula in an in vivo murine model. J Appl Microbiol 2007; 103: 2392-2400.
11. Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 2003; 15: 313-315.
12. Marotta F, Naito Y, Tajiri H, et al. Disrupted mucosal barrier in quiescent ulcerative colitis: the role of metronidazole and of a symbiotic preparation in a pilot cross-over study. J Dig Dis 2003; 4: 180-185.
13. Hotten P, Marotta F, Naito Y, et al. Effects of probiotics, lactitol and rifaximine on intestinal flora and faecal excretion of organic acids in cirrhotics. J Dig Dis 2003; 4: 13-18.
14. Barreto R, Naito Y, Marotta F, et al. Gut flora manipulation mitigates ethanol-induced liver damage and endotoxinemia: experimental comparison between a novel probiotic and metronidazole. Intern Med J 2000; 7: 121-128.
15. Mohania D, Nagpal R, Kumar M, et al. Molecular approaches for identification and characterization of lactic acid bacteria. J Dig Dis 2008; 9: 190-198.
16. Mitsuoka T, Ohno K, Benno Y, Suzuki K, Namba K. The fecal flora of man. Comparison of the newly developed method with the old conventional method for the analysis of intestinal flora. Zentralb Bakteriol 1976; 234: 219-233.
17. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006; 7: 688-693.
18. Metugriachuk Y, Marotta F, Pavasuthipaisit K, et al. The aging gut motility decay: may symbiotics be acting as "implantable" biologic pace-makers? Rejuvenation Res 2006; 9: 342-345.
19. Lighthouse J, Naito Y, Helmy A, et al. Endotoxinemia and benzodiazepine-like substances in compensated cirrhotic patients: a randomized study comparing the effect of rifaximine alone and in association with a symbiotic preparation. Hepatol Res 2004; 28: 155-160.
20. Junger W, Junger WG, Miller K, et al. Early detection of anastomotic leaks after colorectal surgery by measuring endotoxin in the drainage fluid. Hepatogastroenterology 1996; 43: 1523-1529.
21. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. World J Gastroenterol 2005; 11: 2773-2776.
22. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103-1108.
23. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309.
24. Sheth A, Floch M Probiotics and diverticular disease. Nutr Clin Pract 2009; 24: 41-44.
25. Corazza GR, Di Stefano M, Scarpignato C. Treatment of functional bowel disorders: is there room for antibiotics? Digestion 2006; 73 (Suppl 1): 38-46.
26. Tursi A, Brandimarte G, Daffina R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for the patients with recurrent attacks of acute diverticulitis of the colon. Digest Liver Dis 2002; 34: 510-515.
27. Brandimarte G, Tursi A. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med Sci Monit 2004; 10: P170-P173.
28. Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Aiello F. Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis 2007; 22: 1103-1108.
29. Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease. Dig Liver Dis 2008; 40: 737-742.